The Indian Patent Office has refused to grant a patent for dolutegravir. Dolutegravir is an important HIV medicine sold by Viv Healthcare. This will allow generic drugs to enter the market and become affordable. Will help expand access to life-saving treatment. The decision, announced after a controversial battle that lasted nearly a decade, comes after the company filed a patent application for HIV treatment in 2007. According to the order accessed by TOI, the company faced several pre-grant protests from Natco and various advocacy groups between 2013 and 2019. This…
Read MorePatent for HIV drug rejected paves way for entry of generics read full article in Hindi
